Search This Blog

Thursday, May 1, 2025

Amgen beats top-line and bottom-line estimates; reaffirms FY25 outlook

 Amgen Inc. announced on Thursday that its revenue for the first quarter of 2025 stood at $8.1 billion, rising 9% from the same quarter a year earlier and slightly topping estimates.

GAAP net income landed at $1.7 billion, or $3.20 per diluted share, improving from a net loss of $113 million, or $0.21 per share, recorded in the first quarter of 2024. GAAP operating income jumped 20% year on year to $1.2 billion.

"Demand for our products was strong globally in the first quarter. Ongoing new product launches and successful Phase 3 trial results for several products make us feel confident in our long-term growth prospects," CEO Robert Bradway stated.

https://breakingthenews.net/Article/Amgen's-revenue-jumps-9-to-dollar8.1-billion-in-Q1/64026701

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.